Page last updated: 2024-08-26

fulvestrant and butylhydroxybutylnitrosamine

fulvestrant has been researched along with butylhydroxybutylnitrosamine in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chang, C; Han, R; Hsu, I; Li, Y; Messing, EM; Niu, Y; Shang, Z; Tian, J; Wen, S; Yeh, S; Zhang, M	1

Other Studies

1 other study(ies) available for fulvestrant and butylhydroxybutylnitrosamine

Article	Year
Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer. Oncotarget, 2016, May-10, Volume: 7, Issue:19 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Butylhydroxybutylnitrosamine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Integrin alpha5beta1; Interleukin-6; Macrophages; Mice; Neoplasms, Experimental; Treatment Outcome; Tumor Necrosis Factor-alpha; Urinary Bladder Neoplasms	2016

Article

Year

Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer.

Oncotarget, 2016, May-10, Volume: 7, Issue:19

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Butylhydroxybutylnitrosamine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Integrin alpha5beta1; Interleukin-6; Macrophages; Mice; Neoplasms, Experimental; Treatment Outcome; Tumor Necrosis Factor-alpha; Urinary Bladder Neoplasms

2016